Skip to main content

Advertisement

Log in

Promoter –2518 single nucleotide polymorphism of monocyte chemoattractant protein-1 is associated with clinical severity in Behçet’s disease

  • Short Communication
  • Published:
Inflammation Research Aims and scope Submit manuscript

Abstract

Objective

We investigated whether promoter –2518 single nucleotide polymorphism (SNP) of the monocyte chemoattractant protein-1 (MCP-1) gene contributes to susceptibility and clinical features or severity in Behçet’s disease (BD) patients.

Methods

One hundred and thirty-two BD patients and 113 healthy subjects, matched by sex and age, were enrolled. Promoter –2518 polymorphism of the MCP-1 gene was analyzed using automated sequencing. Clinical severity in BD patients was classified into mild, moderate, and severe features and assessed by total severity scores. Clinical features and severity was also compared according to genotypes using either the chi-squared or Fisher’s exact test and Mann–Whitney test, as indicated.

Results

There were no significant differences in alleles (G allele vs. A allele, p = 0.845) and genotypes with –2518 SNP (GG vs. GA vs. AA, p = 0.916) between BD patients and controls. No clinical features were associated with genotypes with –2518 polymorphism of MCP-1. However, the frequency of either GA or AA genotype in patients with moderate lesions and moderate to severe lesions was significantly increased compared with that in patients with the GG genotype (p = 0.044 and p = 0.038, respectively). Total severity scores in the AA genotype were higher than those in the GG and GA genotypes (p = 0.039 and p = 0.003, respectively). Moreover, patients with either the GA or AA genotype had higher scores than those with the GG genotype (p = 0.041).

Conclusions

This study demonstrated that genotypes with A allele with –2518 polymorphism of the MCP-1 gene might have increased risk of severity of clinical features, but not susceptibility to BD.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

References

  1. Sakane T, Takeno M, Suzuki N, Inaba G. Behçet’s disease. N Engl J Med. 1999;341:1284–91.

    Article  PubMed  CAS  Google Scholar 

  2. Marshall SE. Behçet’s disease. Best Pract Res Clin Rheumatol. 2004;18:291–311.

    PubMed  CAS  Google Scholar 

  3. Mege JL, Dilsen N, Sanguedolce V, et al. Overproduction of monocyte derived tumor necrosis factor α, interleukin (IL)-6, IL-8 and increased neutrophil superoxide generation in Behçet’s disease: a comparative study with familial Mediterranean fever and healthy subjects. J Rheumatol. 1993;20:1544–9.

    PubMed  CAS  Google Scholar 

  4. Sahin S, Lawrence R, Direskeneli H, Hamuryudan V, Yazici H, Akoglu T. Monocyte activity in Behçet’s disease. Br J Rheumatol. 1996;35:424–9.

    Article  PubMed  CAS  Google Scholar 

  5. Lee KH, Bang D, Choi ES, Chun WH, Lee ES, Lee S. Presence of circulating antibodies to a disease-specific antigen on cultured human dermal microvascular endothelial cells in patients with Behçet’s disease. Arch Dermatol Res. 1999;291:374–81.

    Article  PubMed  CAS  Google Scholar 

  6. Zouboulis CC, Katsantonis J, Ketteler R, et al. Adamantiades-Behçet’s disease: interleukin-8 is increased in serum of patients with active oral and neurological manifestations and is secreted by small vessel endothelial cells. Arch Dermatol Res. 2000;292:279–84.

    Article  PubMed  CAS  Google Scholar 

  7. Charo IF, Ransohoff RM. The many roles of chemokines and chemokine receptors in inflammation. N Engl J Med. 2006;354:610–21.

    Article  PubMed  CAS  Google Scholar 

  8. Kaburaki T, Fujino Y, Kawashima H, Merino G, Numaga J, Chen J, Matsushima K. Plasma and whole-blood chemokine levels in patients with Behcet’s disease. Graefes Arch Clin Exp Ophthalmol. 2003;241:353–8.

    Article  PubMed  CAS  Google Scholar 

  9. Bozoglu E, Dinc A, Erdem H, Pay S, Simsek I, Kocar IH. Vascular endothelial growth factor and monocyte chemoattractant protein-1 in Behçet’s patients with venous thrombosis. Clin Exp Rheumatol. 2005;23(4 Suppl 38):S42–8.

    PubMed  CAS  Google Scholar 

  10. Cho ML, Kim JY, Ko HJ, Kim YH, Kim WU, Cho CS, Kim HY, Hwang SY. The MCP-1 promoter -2518 polymorphism in Behcet’s disease: correlation between allele types, MCP-1 production and clinical symptoms among Korean patients. Autoimmunity. 2004;37:77–80.

    Article  PubMed  CAS  Google Scholar 

  11. Ozer HT, Erken E, Gunesacar R, Kara O. Serum RANTES, MIP-1α, and MCP-1 levels in Behçet’s disease. Rheumatol Int. 2005;25:487–8.

    Article  PubMed  Google Scholar 

  12. Hou S, Yang P, Du L, Jiang Z, Mao L, Shu Q, Zhou H, Kijlstra A. Monocyte chemoattractant protein-1 –2518 A/G single nucleotide polymorphism in Chinese Han patients with ocular Behçet’s disease. Hum Immunol. 2010;71:79–82.

    Article  PubMed  CAS  Google Scholar 

  13. International Study Group for Behçet’s disease. Criteria for diagnosis of Behçet’s disease. Lancet. 1990;335:1078–80.

    Google Scholar 

  14. Krause I, Rosen Y, Kaplan I, Milo G, Guedj D, Molad Y, Weinberger A. Recurrent aphthous stomatitis in Behçet’s disease: clinical features and correlation with systemic disease expression and severity. J Oral Pathol Med. 1999;28:193–6.

    Article  PubMed  CAS  Google Scholar 

  15. Krause I, Mader R, Sulkes J, Paul M, Uziel Y, Adawi M, Weinberger A. Behçet’s disease in Israel: the influence of ethnic origin on disease expression and severity. J Rheumatol. 2001;28:1033–6.

    PubMed  CAS  Google Scholar 

  16. Choe JY, Chung WT, Lee SW, Lee SS, Choi CB, Park SH, Kim SK. Regional distinction for the clinical severity of Behçet’s disease in Korea: four university-based medical centers study. Clin Exp Rheumatol. 2010;28(4 Suppl 60):S20–6.

    PubMed  Google Scholar 

  17. Yoshimura T, Robinson EA, Tanaka S, Appella E, Leonard EJ. Purification and amino acid analysis of two human monocyte chemoattractants produced by phytohemagglutinin-stimulated human blood mononuclear leukocytes. J Immunol. 1989;142:1956–62.

    PubMed  CAS  Google Scholar 

  18. Gibson T, Laurent R, Highton J, Wilton M, Dyson M, Millis R. Synovial histopathology of Behçet’s syndrome. Ann Rheum Dis. 1981;40:376–81.

    Article  PubMed  CAS  Google Scholar 

  19. Mumcu G, Ergun T, Elbir Y, Eksioglu-Demiralp E, Yavuz S, Atalay T, Direskeneli H. Clinical and immunological effects of azithromycin in Behçet’s disease. J Oral Pathol Med. 2005;34:13–6.

    Article  PubMed  CAS  Google Scholar 

  20. Rovin BH, Lu L, Saxena R. A novel polymorphism in the MCP-1 gene regulatory region that influences MCP-1 expression. Biochem Biophys Res Commun. 1999;259:344–8.

    Article  PubMed  CAS  Google Scholar 

  21. Tucci M, Barnes EV, Sobel ES, Croker BP, Segal MS, Reeves WH, Richards HB. Strong association of a functional polymorphism in the monocyte chemoattractant protein 1 promoter gene with lupus nephritis. Arthritis Rheum. 2004;50:1842–9.

    Article  PubMed  CAS  Google Scholar 

  22. Sanders SK, Crean SM, Boxer PA, Kellner D, LaRosa GJ, Hunt SW 3rd. Functional differences between monocyte chemotactic protein-1 receptor A and monocyte chemotactic protein-1 receptor B expressed in a Jurkat T cell. J Immunol. 2000;165:4877–83.

    PubMed  CAS  Google Scholar 

  23. Cho ML, Yoon BY, Ju JH, Jung YO, Jhun JY, Park MK, Park SH, Cho CS, Kim HY. Expression of CCR2A, an isoform of MCP-1 receptor, is increased by MCP-1, CD40 ligand and TGF-beta in fibroblast like synoviocytes of patients with RA. Exp Mol Med. 2007;39:499–507.

    PubMed  CAS  Google Scholar 

  24. Kural-Seyahi E, Fresko I, Seyahi N, Ozyazgan Y, Mat C, Hamuryudan V, Yurdakul S, Yazici H. The long-term mortality and morbidity of Behçet syndrome: a 2-decade outcome survey of 387 patients followed at a dedicated center. Medicine (Baltimore). 2003;82:60–76.

    Article  Google Scholar 

  25. Yazici H, Başaran G, Hamuryudan V, Hizli N, Yurdakul S, Mat C, Tüzün Y, Ozyazgan Y, Dimitriyadis I. The ten-year mortality in Behçet’s syndrome. Br J Rheumatol. 1996;35:139–41.

    Article  PubMed  CAS  Google Scholar 

  26. Akman-Demir G, Baykan-Kurt B, Serdaroglu P, Gürvit H, Yurdakul S, Yazici H, Bahar S, Aktin E. Seven-year follow-up of neurologic involvement in Behçet syndrome. Arch Neurol. 1996;53:691–4.

    Article  PubMed  CAS  Google Scholar 

  27. Kamoun M, Ben Dhifallah I, Karray E, Zakraoui L, Hamzaoui K. Association of small ubiquitin-like modifier 4 (SUMO4) polymorphisms in a Tunisian population with Behçet’s disease. Clin Exp Rheumatol. 2010;28(4 Suppl 60):S45–9.

    PubMed  Google Scholar 

  28. Kamoun M, Houman MH, Hamzaoui A, Hamzaoui K. Vascular endothelial growth factor gene polymorphisms and serum levels in Behçet’s disease. Tissue Antigens. 2008;72:581–7.

    Article  PubMed  CAS  Google Scholar 

  29. Boiardi L, Atzeni F, Casali B, Farnetti E, Nicoli D, Pipitone N, Catanoso MG, Olivieri I, Cantini F, Salvi F, La Corte R, Triolo G, Filippini D, Paolazzi G, Salvarani C. Toll-like receptor 4 (TLR4) gene polymorphisms in Italian patients with Behçet’s disease. Clin Exp Rheumatol. 2009;27(2 Suppl 53):S43–7.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Jin-Wuk Hur.

Additional information

Responsible Editor: Graham Wallace.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kim, SK., Jang, WC., Ahn, YC. et al. Promoter –2518 single nucleotide polymorphism of monocyte chemoattractant protein-1 is associated with clinical severity in Behçet’s disease. Inflamm. Res. 61, 541–545 (2012). https://doi.org/10.1007/s00011-012-0471-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00011-012-0471-5

Keywords

Navigation